The JUPITER study, recently completed, showed that patients with cardiovascular risk, but with normal levels of LDL < 130 mg/dl and high hs-CRP > 2 mg/dl, who made use of rosuvastatin, compared with placebo, had significantly fewer cardiovascular events.
El estudio JUPITER, recientemente concluido, demostró que pacientes con riesgo cardiovascular, pero con niveles normales de LDL < 130 mg/dl y con PCR-us elevada > 2 mg/dl, que hicieron uso de rosuvastatina, comparados contra placebo, tuvieron significativamente menos desenlaces cardiovasculares.
O estudo JUPITER, recentemente concluído, demonstrou que pacientes com risco cardiovascular, mas com níveis normais de LDL < 130 mg/dl e com PCR-us elevada > 2 mg/dl, que fizeram uso de rosuvastatina, comparados contra placebo, tiveram significativamente menos desfechos cardiovasculares.